VBL to Stop Developing Drug for Psoriasis, Ulcerative ColitisVBL to Stop Developing Drug for Psoriasis, Ulcerative Colitis

Israel's VBL Therapeutics Inc said it would stop developing its experimental inflammatory drug to fight ulcerative colitis and psoriasis, sending its shares tumbling 45% before the bell. Reuters Health Information
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Gastroenterology News Source Type: news